Details of the Drug

General Information of Drug (ID: DMEAOYJ)

Drug Name

Ponesimod

Synonyms

854107-55-4; UNII-5G7AKV2MKP; 5G7AKV2MKP; CHEMBL1096146; Ponesimod [USAN:INN]; Ponesimod,ACT-128800; Ponesimod (ACT-128800); GTPL9320; SCHEMBL15477937; SCHEMBL15477934; DTXSID50234631; MolPort-035-681-391; MolPort-046-033-541; EX-A1417; ZINC34509627; s8241; BDBM50316768; AKOS022180266; DB12016; Compound 8bo [PMID:20446681]; HY-10569; KB-72962; AS-35140; AJ-89002; (2Z,5Z)-5-(3-Chloro-4-((2R)-2,3-dihydroxypropoxy)phenylmethylidene)-3-(2-methylphenyl)-2-(propylimino)-1,3-thiazolidin-

Indication

Disease Entry	ICD 11	Status	REF
Multiple sclerosis	8A40	Approved	[1]
Psoriasis vulgaris	EA90	Phase 2	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

461

Logarithm of the Partition Coefficient (xlogp)

4.6

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 3872 mcgh/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 109 mcg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 4 h [3]
Clearance: The clearance of drug is 3.8 L/h [3]
Elimination: 57.3-79.6% of a radiolabelled oral dose is recovered in the feces, with 16-26% as the unmetabolized parent compound and 22% as the M12 metabolite [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 33 hours [3]
Metabolism: The drug is metabolized via the CYP2J2, CYP3A4, CYP3A5, CYP4F3A, and CYP4F12 to the M12 metabolite [4]
Vd: The volume of distribution (Vd) of drug is 160 L [3]

Chemical Identifiers

Formula: C23H25ClN2O4S
IUPAC Name: (5Z)-5-[[3-chloro-4-[(2R)-2,3-dihydroxypropoxy]phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one
Canonical SMILES: CCCN=C1N(C(=O)/C(=C/C2=CC(=C(C=C2)OC[C@@H](CO)O)Cl)/S1)C3=CC=CC=C3C
InChI: InChI=1S/C23H25ClN2O4S/c1-3-10-25-23-26(19-7-5-4-6-15(19)2)22(29)21(31-23)12-16-8-9-20(18(24)11-16)30-14-17(28)13-27/h4-9,11-12,17,27-28H,3,10,13-14H2,1-2H3/b21-12-,25-23?/t17-/m1/s1
InChIKey: LPAUOXUZGSBGDU-ULCCENQXSA-N

Cross-matching ID

PubChem CID: 11363176
CAS Number: 854107-55-4
DrugBank ID: DB12016
TTD ID: D0Y4SI

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sphingosine-1-phosphate receptor 1 (S1PR1)	TT9JZCK	S1PR1_HUMAN	Agonist	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
2	ClinicalTrials.gov (NCT00852670) ACT-128800 in Psoriasis. U.S. National Institutes of Health.
3	FDA Approved Drug Products: Ponvory (Ponesimod) Oral Tablet
4	Lade JM, Avery LB, Bumpus NN: Human biotransformation of the nonnucleoside reverse transcriptase inhibitor rilpivirine and a cross-species metabolism comparison. Antimicrob Agents Chemother. 2013 Oct;57(10):5067-79. doi: 10.1128/AAC.01401-13. Epub 2013 Aug 5.